Cure My Disease

Don't miss your cure!

 Log in / Sign up

COVID-19 blood clot mystery: new study aims to unravel why some patients develop dangerous clots

NCT ID NCT04356950

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at blood clotting in 175 hospitalized COVID-19 patients. Researchers used a special test to measure how quickly and strongly blood clots form, and whether a protein called thrombomodulin can slow this process. The goal was to understand why some COVID-19 patients develop dangerous blood clots, which could help guide future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help doctors identify which COVID-19 patients are at highest risk for blood clots, leading to better prevention and treatment strategies.
What could go wrong
This is an observational study, not a treatment trial. It does not test any new drug or therapy, so it cannot directly improve patient outcomes. The findings may not apply to all COVID-19 patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

175 people

The number who actually took part.

Started

Apr 2020

Finished

Feb 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consecutive patients hospitalized for SARS-CoV-2 infection with symptomatology / severity requiring hospital treatment.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with SARS-CoV-2 infection entering hospitalization with or without resuscitation * The patient (or their carer) must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan Exclusion Criteria: * Pregnant or breastfeeding patient * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * Thrombotic events during treatment: flare-up of venous thromboembolism, flare-up of atherothrombosis. * Long-term anticoagulant treatment (anti-vitamin K, direct oral anticoagulant). * Chronic anti-aggregation treatment. * Pre-existing constitutive or acquired known coagulation pathology: hemorrhagic diseases (thrombocytopenia, thrombocytopathy, hemophilia, von Willebrand's disease, hemorrhagiparous factor deficiency), and for thrombophilia (deficits in antithrombin, protein C or S , Factor V Leiden or Prothrombin 20201A mutation).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood coagulation disorders are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

blood coagulation disease COVID-19 disseminated intravascular coagulation infectious disease with sepsis Sepsis thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood coagulation disorders COVID -19 Disseminated intravascular coagulation Sepsis Thrombin

Contacts and locations

Locations

  • CHU de Bordeaux

    Bordeaux, France

  • CHU de Limoges

    Limoges, France

  • CHU de Montpellier

    Montpellier, France

  • CHU de Nimes

    Nîmes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.